Based on the data at the interim analysis of Feb 25, 2021, it is estimated that the chance for success, that the survival benefit of ADI PEG-20 over the control group is statistically significant at the end of the trial, will be greater than 80%.
The Phase III interim analysis of the Polaris-KY (6550TW) clinical trial in the U.S. for lung mesothelial cancer (a type of lung cancer) was released on February 25, 2012. Based on current interim data, the overall success rate for the final trial is estimated to be above 80% (80-100%). The experts explained that this means …
Nanotein Technologies, Inc., an innovative startup biotechnology company in the San Francisco Bay Area, and Polaris Group, a developer of novel treatments for cancer, announced today they have entered into a strategic partnership to advance Nanotein’s protein-based solutions for superior cellular therapy manufacturing.
Taipei, September 17, 2020 – Polaris Group announced today that the first patient has been dosed in a phase 1B trial of ADI‑PEG 20 in combination with Radiotherapy and Temozolomide for the treatment of Newly Diagnosed Glioblastoma Multiforme (GBM). The Lead Investigator is Dr. Wei from Linkou Chang Gung Memorial Hospital. There will be 26 patients enrolled in this phase 1B trial.
Polaris Group announces closing of US$100 Million fund raising through private placement.
Pancreatic cancer is notoriously difficult to treat. One potential opportunity for targeting pancreatic cancer is through its modified amino acid metabolism. Specifically, depriving arginine-dependent tumor cells of arginine can lead to cell death. To achieve this, a polyethylene glycol (PEG)-conjugated arginine deiminase construct (ADI-PEG20) was previously designed and tested as a monotherapy in clinical studies with limited success.
SAN DIEGO, February 22, 2019 – Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer.
SAN DIEGO, February 22, 2019 – Polaris Group announced today that Wayne Lin, MBA has been appointed as the Chief Operating Officer.
SAN DIEGO, July 9, 2018 — Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board.
SAN DIEGO, July 8, 2018 — Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group), a biopharmaceutical company focused on developing novel drugs for cancer, announced that James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. have joined its Scientific Advisory Board. As one of the world’s most renowned scientists, Dr. Allison’s fundamental research on the mechanisms …
